|
|
Prepublished online as a Blood First Edition Paper on November 7, 2002; DOI 10.1182/blood-2002-05-1343.
 Previous Article | Table of Contents | Next Article 
Blood, 1 March 2003, Vol. 101, No. 5, pp. 1919-1927
NEOPLASIA
NPM-ALK transgenic mice spontaneously develop T-cell
lymphomas and plasma cell tumors
Roberto Chiarle,
Jerald Z. Gong,
Ilaria Guasparri,
Anna Pesci,
Jonjing Cai,
Jian Liu,
William J. Simmons,
Girish Dhall,
Jennifer Howes,
Roberto Piva, and
Giorgio Inghirami
From the Department of Pathology and Kaplan
Comprehensive Cancer Center, and Department of Pediatric Oncology, New
York University School of Medicine, New York; Department of Pathology
and Centro di Ricerca in Medicina Sperimentale (CERMS), University of
Torino, Torino, Italy; Department of Pathology, University
of Verona, Verona, Italy; Department of Pathology,
University of Cornell, New York, NY.
Anaplastic Large Cell
Lymphomas (ALCLs) carry translocations in which the
anaplastic lymphoma kinase (ALK) gene is juxtaposed to various genes, the most common of which is the NPM/B23
gene. ALK fusion proteins result in the constitutive activation of ALK tyrosine kinase, thereby enhancing proliferation and increasing cell
survival. A direct role for NPM-ALK in cellular transformation has been
shown in vitro with immortalized cell lines and in vivo using
retroviral transfer experiments. Nonetheless, there is no direct
evidence of its oncogenic potential in T lymphocytes, which represent
the most common target of ALK chimeras. Here, we describe a new mouse
model of lymphomagenesis in which human NPM-ALK transcription was
targeted to T cells. NPM-ALK transgenic (Tg) mice were born with the
expected mendelian distribution, normal lymphoid organs, and a normal
number and proportion of helper and suppressor T cells. However, after
a short period of latency, all NPM-ALK Tg mice developed malignant
lymphoproliferative disorders (mean survival, 18 weeks). NPM-ALK Tg
thymic lymphomas displayed a T-cell phenotype characteristic of
immature thymocytes and frequently coexpressed surface CD30. A
subset of the NPM-ALK Tg mice also developed clonal B-cell plasma
cell neoplasms. These tumors arose in peripheral lymphoid organs
(plasmacytomas) or within the bone marrow and often led to peripheral
neuropathies and limb paralysis. Our NPM-ALK Tg mice are a suitable
model to dissect the molecular mechanisms of ALK-mediated
transformation and to investigate the efficacy of new therapeutic
approaches for the treatment of human ALCL in vivo.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
C. Ambrogio, C. Martinengo, C. Voena, F. Tondat, L. Riera, P. F. di Celle, G. Inghirami, and R. Chiarle
NPM-ALK Oncogenic Tyrosine Kinase Controls T-Cell Identity by Transcriptional Regulation and Epigenetic Silencing in Lymphoma Cells
Cancer Res.,
November 15, 2009;
69(22):
8611 - 8619.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. P. Mosse, A. Wood, and J. M. Maris
Inhibition of ALK Signaling for Cancer Therapy
Clin. Cancer Res.,
September 15, 2009;
15(18):
5609 - 5614.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Marzec, Q. Zhang, A. Goradia, P. N. Raghunath, X. Liu, M. Paessler, H. Y. Wang, M. Wysocka, M. Cheng, B. A. Ruggeri, et al.
Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)
PNAS,
December 30, 2008;
105(52):
20852 - 20857.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Ambrogio, C. Voena, A. D. Manazza, C. Martinengo, C. Costa, T. Kirchhausen, E. Hirsch, G. Inghirami, and R. Chiarle
The Anaplastic Lymphoma Kinase Controls Cell Shape and Growth of Anaplastic Large Cell Lymphoma through Cdc42 Activation
Cancer Res.,
November 1, 2008;
68(21):
8899 - 8907.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Accornero, G. Lattanzio, T. Mangano, R. Chiarle, R. Taulli, F. Bersani, P. E. Forni, S. Miretti, C. Scuoppo, W. Dastru, et al.
An In vivo Model of Met-Driven Lymphoma as a Tool to Explore the Therapeutic Potential of Met Inhibitors
Clin. Cancer Res.,
April 1, 2008;
14(7):
2220 - 2226.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. G. Christensen, H. Y. Zou, M. E. Arango, Q. Li, J. H. Lee, S. R. McDonnell, S. Yamazaki, G. R. Alton, B. Mroczkowski, and G. Los
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma
Mol. Cancer Ther.,
December 1, 2007;
6(12):
3314 - 3322.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. B. Staber, P. Vesely, N. Haq, R. G. Ott, K. Funato, I. Bambach, C. Fuchs, S. Schauer, W. Linkesch, A. Hrzenjak, et al.
The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling
Blood,
November 1, 2007;
110(9):
3374 - 3383.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. M. Amin and R. Lai
Pathobiology of ALK+ anaplastic large-cell lymphoma
Blood,
October 1, 2007;
110(7):
2259 - 2267.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Galietta, R. H. Gunby, S. Redaelli, P. Stano, C. Carniti, A. Bachi, P. W. Tucker, C. J. Tartari, C.-J. Huang, E. Colombo, et al.
NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma
Blood,
October 1, 2007;
110(7):
2600 - 2609.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Leventaki, E. Drakos, L. J. Medeiros, M. S. Lim, K. S. Elenitoba-Johnson, F. X. Claret, and G. Z. Rassidakis
NPM-ALK oncogenic kinase promotes cell-cycle progression through activation of JNK/cJun signaling in anaplastic large-cell lymphoma
Blood,
September 1, 2007;
110(5):
1621 - 1630.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Liu, Z. Liu, S.-W. Jang, Z. Ma, K. Shinmura, S. Kang, S. Dong, J. Chen, K. Fukasawa, and K. Ye
Sumoylation of nucleophosmin/B23 regulates its subcellular localization, mediating cell proliferation and survival
PNAS,
June 5, 2007;
104(23):
9679 - 9684.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Li, D. P. Sejas, S. Burma, D. J. Chen, and Q. Pang
Nucleophosmin suppresses oncogene-induced apoptosis and senescence and enhances oncogenic cooperation in cells with genomic instability
Carcinogenesis,
June 1, 2007;
28(6):
1163 - 1170.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Voena, C. Conte, C. Ambrogio, E. Boeri Erba, F. Boccalatte, S. Mohammed, O. N. Jensen, G. Palestro, G. Inghirami, and R. Chiarle
The Tyrosine Phosphatase Shp2 Interacts with NPM-ALK and Regulates Anaplastic Lymphoma Cell Growth and Migration
Cancer Res.,
May 1, 2007;
67(9):
4278 - 4286.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. V. Galkin, J. S. Melnick, S. Kim, T. L. Hood, N. Li, L. Li, G. Xia, R. Steensma, G. Chopiuk, J. Jiang, et al.
Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK
PNAS,
January 2, 2007;
104(1):
270 - 275.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Fawal, F. Armstrong, S. Ollier, H. Dupont, C. Touriol, B. Monsarrat, G. Delsol, B. Payrastre, and D. Morello
A "liaison dangereuse" between AUF1/hnRNPD and the oncogenic tyrosine kinase NPM-ALK
Blood,
October 15, 2006;
108(8):
2780 - 2788.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Qiu, R. Lai, Q. Lin, E. Lau, D. M. Thomazy, D. Calame, R. J. Ford, L. W. Kwak, R. A. Kirken, and H. M. Amin
Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells
Blood,
October 1, 2006;
108(7):
2407 - 2415.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Quintanilla-Martinez, S. Pittaluga, C. Miething, M. Klier, M. Rudelius, T. Davies-Hill, N. Anastasov, A. Martinez, A. Vivero, J. Duyster, et al.
NPM-ALK-dependent expression of the transcription factor CCAAT/enhancer binding protein beta in ALK-positive anaplastic large cell lymphoma
Blood,
September 15, 2006;
108(6):
2029 - 2036.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Jacobsen
Anaplastic Large-Cell Lymphoma, T-/Null-Cell Type
Oncologist,
July 1, 2006;
11(7):
831 - 840.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Kasprzycka, M. Marzec, X. Liu, Q. Zhang, and M. A. Wasik
From the Cover: Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3
PNAS,
June 27, 2006;
103(26):
9964 - 9969.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Li, D. P. Sejas, R. Rani, T. Koretsky, G. C. Bagby, and Q. Pang
Nucleophosmin Regulates Cell Cycle Progression and Stress Response in Hematopoietic Stem/Progenitor Cells
J. Biol. Chem.,
June 16, 2006;
281(24):
16536 - 16545.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Piva, R. Chiarle, A. D. Manazza, R. Taulli, W. Simmons, C. Ambrogio, V. D'Escamard, E. Pellegrino, C. Ponzetto, G. Palestro, et al.
Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas
Blood,
January 15, 2006;
107(2):
689 - 697.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Mathas, K. Johrens, S. Joos, A. Lietz, F. Hummel, M. Janz, F. Jundt, I. Anagnostopoulos, K. Bommert, P. Lichter, et al.
Elevated NF-{kappa}B p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas
Blood,
December 15, 2005;
106(13):
4287 - 4293.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Ambrogio, C. Voena, A. D. Manazza, R. Piva, L. Riera, L. Barberis, C. Costa, G. Tarone, P. Defilippi, E. Hirsch, et al.
p130Cas mediates the transforming properties of the anaplastic lymphoma kinase
Blood,
December 1, 2005;
106(12):
3907 - 3916.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Bacchiocchi, G. Baldanzi, D. Carbonari, C. Capomagi, E. Colombo, W. J. van Blitterswijk, A. Graziani, and F. Fazioli
Activation of {alpha}-diacylglycerol kinase is critical for the mitogenic properties of anaplastic lymphoma kinase
Blood,
September 15, 2005;
106(6):
2175 - 2182.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Korgaonkar, J. Hagen, V. Tompkins, A. A. Frazier, C. Allamargot, F. W. Quelle, and D. E. Quelle
Nucleophosmin (B23) Targets ARF to Nucleoli and Inhibits Its Function
Mol. Cell. Biol.,
February 15, 2005;
25(4):
1258 - 1271.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Li, X. Zhang, D. P. Sejas, G. C. Bagby, and Q. Pang
Hypoxia-induced Nucleophosmin Protects Cell Death through Inhibition of p53
J. Biol. Chem.,
October 1, 2004;
279(40):
41275 - 41279.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T.-L. Gu, Z. Tothova, B. Scheijen, J. D. Griffin, D. G. Gilliland, and D. W. Sternberg
NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a
Blood,
June 15, 2004;
103(12):
4622 - 4629.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Bonvini, H. D. Rosa, N. Vignes, and A. Rosolen
Ubiquitination and Proteasomal Degradation of Nucleophosmin-Anaplastic Lymphoma Kinase Induced by 17-Allylamino-Demethoxygeldanamycin: Role of the Co-Chaperone Carboxyl Heat Shock Protein 70-Interacting Protein
Cancer Res.,
May 1, 2004;
64(9):
3256 - 3264.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. D. Gascoyne, L. Lamant, J. I. Martin-Subero, V. S. Lestou, N. L. Harris, H.-K. Muller-Hermelink, J. F. Seymour, L. J. Campbell, D. E. Horsman, I. Auvigne, et al.
ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases
Blood,
October 1, 2003;
102(7):
2568 - 2573.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. De Paepe, M. Baens, H. van Krieken, B. Verhasselt, M. Stul, A. Simons, B. Poppe, G. Laureys, P. Brons, P. Vandenberghe, et al.
ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma
Blood,
October 1, 2003;
102(7):
2638 - 2641.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Onciu, F. G. Behm, J. R. Downing, S. A. Shurtleff, S. C. Raimondi, Z. Ma, S. W. Morris, W. Kennedy, S. C. Jones, and J. T. Sandlund
ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: report of 2 cases
Blood,
October 1, 2003;
102(7):
2642 - 2644.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
